All News

21 June 2010

Pfizer Prepares For Voluntary Withdrawal Of U.S. New Drug Application And For Discontinuation Of Commercial vailability Of MylotargAntibodies

18 June 2010

New Phase II study in gout patients shows Novartis ACZ885 prevented acute flares better than standard anti-inflammatory therapyAntibodies

17 June 2010

Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye DiseaseAntibodies

17 June 2010

HUMAN GENOME SCIENCES AND GLAXOSMITHKLINE ANNOUNCE FULL PRESENTATION AT EULAR OF BLISS-76 PHASE 3 STUDY RESULTS FOR BENLYSTA® IN SYSTEMIC LUPUS ERYTHEMATOSUSAntibodies

16 June 2010

New Data From EMBLEM(TM) Study Show Pipeline Drug Epratuzumab Provided Significant Efficacy for Patients Suffering From Moderate to Severe Systemic Lupus ErythematosusAntibodies

16 June 2010

New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against RheumatismAntibodies

16 June 2010

Long-term Cimzia® (certolizumab pegol) Data Demonstrated Rapid Sustained Improvements in Clinical Outcomes and Quality of Life in Moderate to Severe Rheumatoid Arthritis (RA) PatientsAntibodies

15 June 2010

Trubion Provides Update on Clinical Development in RAAntibodies

15 June 2010

Micromet’s Blinatumomab Induces Durable Remissions in Patients with Relapsed Non-Hodgkin’s LymphomaAntibodies

15 June 2010

Immunomedics Doses First Patient in Phase I/II Study of Milatuzumab-Doxorubicin Conjugate for Multiple Myeloma TherapyAntibodies

11 June 2010

Human Genome Sciences Announces Submission of Biologics License Application to FDA for BENLYSTA (belimumab)Antibodies

10 June 2010

HUMAN GENOME SCIENCES ANNOUNCES RESULTS OF RANDOMIZED PHASE 2 TRIAL OF MAPATUMUMAB IN MULTIPLE MYELOMAAntibodies

10 June 2010

ARCALYST(R) (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 Trial of Prevention of Gout Flares in Patients Initiating Allopurinol TherapyAntibodies

9 June 2010

Immunomedics Presents New Antibody for Pretargeting Epithelial Cancers at Medical ConferenceAntibodies

8 June 2010

New licence extension for RoACTEMRA in EuropeAntibodies

8 June 2010

Immunomedics Reports First Clinical Experience With New Generation of Bispecific AntibodyAntibodies

8 June 2010

Sanofi Pasteur Partners With Vivalis For The Discovery of Human Monoclonal Antibodies Against Infectious DiseasesAntibodies

7 June 2010

Immunomedics Reports Updated Results of Targeted Therapy for Advanced Pancreatic CancerAntibodies

7 June 2010

Micromet Presents Interim Update on Phase 1 Study of MT110 in Patients with Advanced Solid TumorsAntibodies

7 June 2010

Celldex Therapeutics Presents New Clinical Data from Phase 2 Study of CDX-011 in Metastatic Melanoma at 46th Annual ASCO MeetingAntibodies

7 June 2010

ImmunoGen, Inc. Announces Encouraging IMGN388 Clinical Data Reported at ASCOAntibodies

7 June 2010

Progenics Phase 1 PSMA ADC Study Presented in New “Trials in Progress” Poster Session at ASCO Annual MeetingAntibodies

7 June 2010

Genmab Presents Data from a Pivotal Trial of Zalutumumab Versus Best Supportive Care in Patients with Refractory Head and Neck CancerAntibodies

7 June 2010

Regulatory update – Benlysta (belimumab)Antibodies

7 June 2010

Phase III Study Showed Avastin-Based Regimen Helped Women with Advanced Ovarian Cancer Live Longer Without Their Disease WorseningAntibodies

7 June 2010

Pooled Results of Early Endpoints from Phase 3 Trials of Genasense in Advanced Melanoma Presented at ASCOAntibodies

7 June 2010

Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic MelanomaAntibodies

6 June 2010

Alder Biopharmaceuticals’ ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia in Phase 2a Clinical Trial in Non-Small Cell Lung Cancer PatientsAntibodies

5 June 2010

AVEO Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating SCH 900105 (AV-299) in Non-Small Cell Lung CancerAntibodies

5 June 2010

Interim Positive Results From Phase 2b Brain Cancer Study With Rindopepimut (PF-04948568 or CDX-110) Presented at 46th Annual ASCO MeetingAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

c-Met-Targeted Antibody Therapy Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Ustekinumab (Stelara) Biosimilars Pipeline Review

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

TSLP Pipeline Review

CD73 Inhibitor Pipeline Review

CCR8-Targeted Antibody Immunotherapy Pipeline Review